Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give their agreement to participate and are willing to follow all study procedures for the full duration of the trial
- People who are male, or if female, have had a surgical procedure to prevent pregnancy or have not had a menstrual period for at least one year
- People who are 50 years of age or older
- People who have been diagnosed with a specific type of age-related macular degeneration (AMD) called dry AMD with Geographic Atrophy (GA) — a form of damage to the back of the eye — where the damaged area does not cover the central point of vision
- People where the total area of damage to the back of the eye falls within a specific size range (confirm with trial site for exact measurements)
- People where, if there are multiple patches of damage, at least one patch meets a minimum size requirement (confirm with trial site)
- People whose best corrected vision (with glasses or contact lenses) falls within a specific range — roughly between near-normal and moderately reduced vision (confirm with trial site)
- People who have never received any treatment for AMD, other than oral vitamin or mineral supplements
Who may not be able to join:
- People who have taken part in another clinical drug trial within the past 60 days
- People who are currently using a class of medications called SGLT2 inhibitors
- People who have a history of low blood pressure with symptoms, or who have low blood pressure with symptoms at the time of screening
- People who have Type 1 or Type 2 Diabetes
- People who have severe kidney disease or whose kidneys are functioning below a certain level (confirm with trial site)
- People who have a history of heart failure
- People who have had a serious allergic reaction to the study drug (dapagliflozin/FARXIGA) or any of its ingredients
- People who have another medical condition, or a history of drug or alcohol misuse, or a mental health or cognitive condition that the study doctor believes could interfere with safely following the study procedures
- People who have previously received any treatment for AMD (wet or dry type) or any injection into the eye for any reason, other than oral supplements
- People who have had eye surgery or a laser procedure to the eye within 3 months before joining the trial
- People who have had an eye or eyelid infection, or eye surface inflammation in the past 12 weeks
- People who have ever had a laser treatment to the central area of the back of the eye (the macula), for any reason
- People whose eye shows signs of a specific type of abnormal blood vessel growth at the back of the eye (choroidal neovascularization)
- People who are already enrolled in another interventional clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rajendra S Apte, MD PhD, Washington University School of Medicine
Phone: 314-286-2946
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.